D A Garcia

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. ncbi Update on the diagnosis and management of pulmonary embolism
    David Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Br J Haematol 131:301-12. 2005
  2. doi Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants
    D Garcia
    University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
    J Thromb Haemost 11:245-52. 2013
  3. pmc Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    David A Garcia
    University of New Mexico, MSC07 4025, Albuquerque, NM 87131, USA
    Chest 141:e24S-43S. 2012
  4. doi Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation
    David A Garcia
    Anticoagulation Clinic, University of New Mexico Health Sciences Center, 1 University of New Mexico MSC, 07 4025, Albuquerque, NM 87131, USA
    Thromb Res 129:9-16. 2012
  5. doi Warfarin and pharmacogenomic testing: the case for restraint
    D A Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    Clin Pharmacol Ther 84:303-5. 2008
  6. doi Duration of anticoagulant therapy for patients with venous thromboembolism
    David Garcia
    Internal Medicine, University of New Mexico, MSC10 5550, Albuquerque, NM 87131, USA
    Thromb Res 123:S62-4. 2008
  7. doi A prospective, controlled trial of a pharmacy-driven alert system to increase thromboprophylaxis rates in medical inpatients
    David A Garcia
    Division of Hematology Oncology, University of New Mexico School of Medicine, New Mexico, USA
    Blood Coagul Fibrinolysis 20:541-5. 2009
  8. doi The new oral anticoagulants
    David Garcia
    University of New Mexico, MSC08 4630, 900 Camino de Salud NE, Albuquerque, NM 87131 0001
    Blood 115:15-20. 2010
  9. ncbi Current therapeutic strategies and future perspectives for the treatment of venous thromboembolism
    David A Garcia
    University of New Mexico, Albuquerque, NM, USA
    Curr Pharm Des 16:3475-7. 2010
  10. doi New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs
    David A Garcia
    Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico, MSC10 5550, Albuquerque, NM 87131, USA
    Thromb Haemost 104:1099-105. 2010

Detail Information

Publications28

  1. ncbi Update on the diagnosis and management of pulmonary embolism
    David Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Br J Haematol 131:301-12. 2005
    ..However, newer treatment options such as low-molecular-weight heparins and the pentasaccharides may offer similar efficacy with improved convenience...
  2. doi Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants
    D Garcia
    University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
    J Thromb Haemost 11:245-52. 2013
    ....
  3. pmc Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    David A Garcia
    University of New Mexico, MSC07 4025, Albuquerque, NM 87131, USA
    Chest 141:e24S-43S. 2012
    ..Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT...
  4. doi Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation
    David A Garcia
    Anticoagulation Clinic, University of New Mexico Health Sciences Center, 1 University of New Mexico MSC, 07 4025, Albuquerque, NM 87131, USA
    Thromb Res 129:9-16. 2012
    ....
  5. doi Warfarin and pharmacogenomic testing: the case for restraint
    D A Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    Clin Pharmacol Ther 84:303-5. 2008
  6. doi Duration of anticoagulant therapy for patients with venous thromboembolism
    David Garcia
    Internal Medicine, University of New Mexico, MSC10 5550, Albuquerque, NM 87131, USA
    Thromb Res 123:S62-4. 2008
    ..This paper will discuss evidence and considerations (including the issue of bleeding risk) that may be relevant to decisions about duration of anticoagulant therapy for patients with VTE...
  7. doi A prospective, controlled trial of a pharmacy-driven alert system to increase thromboprophylaxis rates in medical inpatients
    David A Garcia
    Division of Hematology Oncology, University of New Mexico School of Medicine, New Mexico, USA
    Blood Coagul Fibrinolysis 20:541-5. 2009
    ....
  8. doi The new oral anticoagulants
    David Garcia
    University of New Mexico, MSC08 4630, 900 Camino de Salud NE, Albuquerque, NM 87131 0001
    Blood 115:15-20. 2010
    ..This review summarizes published clinical trial data pertinent to apixaban, dabigatran, and rivaroxaban...
  9. ncbi Current therapeutic strategies and future perspectives for the treatment of venous thromboembolism
    David A Garcia
    University of New Mexico, Albuquerque, NM, USA
    Curr Pharm Des 16:3475-7. 2010
    ..The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue...
  10. doi New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs
    David A Garcia
    Department of Internal Medicine, University of New Mexico Health Sciences Center, University of New Mexico, MSC10 5550, Albuquerque, NM 87131, USA
    Thromb Haemost 104:1099-105. 2010
    ....
  11. doi Thrombosis and malignancy: a case-based review
    David Garcia
    Division of Hematology Oncology, University of New Mexico Cancer Center, Albuquerque, NM 87131, USA
    Semin Hematol 48:259-63. 2011
    ..We will make evidence-based recommendations wherever possible; however, several of the scenarios here were included because pertinent high-quality evidence does not exist...
  12. doi Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum
    David A Garcia
    University of New Mexico School of Medicine, Albuquerque, NM, USA
    Ann Pharmacother 42:979-88. 2008
    ....
  13. doi Reducing the risk for stroke in patients who have atrial fibrillation
    David A Garcia
    Department of Internal Medicine, 1 University of New Mexico, MSC10 5550, Albuquerque, NM 87131, USA
    Cardiol Clin 26:267-75, vii. 2008
    ....
  14. doi Update in the treatment of venous thromboembolism
    David A Garcia
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
    Semin Respir Crit Care Med 29:40-6. 2008
    ..In addition to presenting evidence relevant to the optimal duration of warfarin therapy, we highlight circumstances under which extended therapy with a parenteral agent such as a low molecular weight heparin might be preferable...
  15. ncbi The risk of hemorrhage among patients with warfarin-associated coagulopathy
    David A Garcia
    Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    J Am Coll Cardiol 47:804-8. 2006
    ..Among warfarin-treated patients with international normalized ratio (INR) >5, we sought to determine the risk of major bleeding within 30 days...
  16. ncbi Antithrombotic therapy in atrial fibrillation
    David A Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Clin Geriatr Med 22:155-66, x. 2006
    ....
  17. ncbi Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population
    David Garcia
    Department of Medicine, Division of General Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
    Chest 127:2049-56. 2005
    ....
  18. ncbi Stroke prevention in elderly patients with atrial fibrillation
    David Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Lancet 370:460-1. 2007
  19. ncbi Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice
    David A Garcia
    Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    J Thromb Thrombolysis 18:199-203. 2004
    ..We tested the hypothesis that there is significant practice variation amongst clinicians caring for patients with MHV who require temporary cessation of their warfarin therapy...
  20. ncbi False-negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosis
    Edward N Libby
    Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico 87131 0001, USA
    Am J Hematol 81:284-9. 2006
    ..There is a need for standardization of optimized fVL genetic testing methods. Further education of ordering physicians on the limitations of genetic testing is necessary...
  21. doi Challenges and benefits of an inpatient anticoagulation service: one hospital's experience
    Allison Burnett
    Inpatient Pharmacy Department, University of New Mexico Hospital, 2211 Lomas Blvd NE, Albuquerque, NM 87106, USA
    J Thromb Thrombolysis 31:344-52. 2011
    ....
  22. doi Novel anticoagulants and the future of anticoagulation
    David Garcia
    University of New Mexico, Albuquerque, 87131 0001, USA
    Thromb Res 123:S50-5. 2009
    ....
  23. doi Treatment of venous thromboembolism: guidelines translated for the clinician
    M Houman Fekrazad
    Division of Hematology Oncology, University of New Mexico, Albuquerque, NM, USA
    J Thromb Thrombolysis 28:270-5. 2009
    ..Prevention of postphlebitic syndrome is discussed as well. We will conclude with a brief discussion of future directions including several novel therapeutic anticoagulants...
  24. doi Cancer-associated thrombosis
    John Winters
    Department of Internal Medicine, University of New Mexico School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Hematol Oncol Clin North Am 24:695-707, viii. 2010
    ..Outcomes may be improved by an evidence-based approach to management with consideration of practice guidelines...
  25. doi Perioperative management of anticoagulation: guidelines translated for the clinician
    Erik P Kraai
    University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    J Thromb Thrombolysis 28:16-22. 2009
    ..We aimed to summarize and provide our opinion about the recommendations from the recent 8th edition of the American College of Chest Physicians (ACCP) guidelines for the perioperative management of antithrombotic therapy...
  26. doi Risk of thromboembolism with short-term interruption of warfarin therapy
    David A Garcia
    Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Arch Intern Med 168:63-9. 2008
    ..We aimed to assess the frequency of thromboembolism and bleeding within a large cohort of patients whose warfarin therapy was temporarily withheld for an outpatient invasive procedure...
  27. ncbi A survey of oral vitamin K use by anticoagulation clinics
    Edward N Libby
    University of New Mexico Hospital, Department of Internal Medicine 5ACC, 2211 Lomas NE, Albuquerque, NM 87131, USA
    Arch Intern Med 162:1893-6. 2002
    ....
  28. ncbi How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review
    David A Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA
    Blood 110:3122-7. 2007
    ..Whenever possible, the recommendations are based on evidence; however, in many cases, insufficient evidence exists, so the recommendation is experiential...